Efficacy and safety of tepotinib in MET‑altered non‑small cell lung cancer: a meta-analysis.

Jiayi Xiao, Qinyi Cai, Xinyuan Li, Degang Zhang

Abstract readMeta-AnalysisSystematic Review

In one paragraph

Synthesis in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jiayi XiaoThe Second Clinical Medical School, Lanzhou University, Lanzhou, 730030, China.

Qinyi CaiThe Second Clinical Medical School, Lanzhou University, Lanzhou, 730030, China.

Xinyuan LiThe First Hospital and Clinical Medical School, Lanzhou University, Lanzhou, 730030, China.

Degang ZhangThe Second Clinical Medical School, Lanzhou University, Lanzhou, 730030, China. zhangdg18@lzu.edu.cn.

Funding

Gansu Health Industry Scientific Research Program GSWSKY2021-061Lanzhou University Second Hospital's Cuiying Scientific Training Program for Undergraduates CYXZ2022-35Natural Science Foundation of Gansu Province 25JRRA588

6 · The paper itself

Abstract

MET exon 14 skipping mutations (METex14) or amplification drives a subset of non-small cell lung cancer (NSCLC). Tepotinib, a selective MET tyrosine kinase inhibitor (TKI), has shown promise in early trials; however, comparative efficacy and safety data across MET-altered subpopulations remain limited. This systematic review of six studies (546 patients) assessed the clinical outcomes of Tepotinib in METex14 or MET-amplified NSCLC. The primary endpoint was objective response rate (ORR); secondary endpoints included disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. The pooled objective response rate (ORR) was 52% (95% CI: 48–56%) and a disease control rate (DCR) of 76% (95% CI: 72–80%). Median PFS was 10.16 months, and median OS was 14.67 months. Subgroup analyses revealed no significant differences in ORR between METex14 (52%) and MET amplification (53%, p = 0.905) or between monotherapy (51%) and combination therapy (56%, p = 0.242). Common treatment-related adverse events (TRAEs) were grade 1–2 peripheral edema (50%) and diarrhea (36%); grade ≥ 3 TRAEs were infrequent (8% for edema). In conclusion, Tepotinib demonstrated comparable efficacy in METex14 and MET-amplified NSCLC with a manageable safety profile. The PFS benefit of combination therapy warrants further randomized trials. These findings support Tepotinib as a valuable therapeutic option for MET-altered NSCLC.

Indexed as

Antineoplastic AgentsCarcinoma, Non-Small-Cell LungLung NeoplasmsPiperazinesPiperidinesProtein Kinase InhibitorsProto-Oncogene Proteins c-metPyridazinesPyrimidinesHumansMutationTreatment OutcomeAntineoplastic AgentsMET protein, humanPiperazinesPiperidinesProtein Kinase InhibitorsProto-Oncogene Proteins c-metPyridazinesPyrimidinestepotinibmeta-analysisMET amplificationMET exon 14non-small cell lung cancerTepotinib

Identifiers

PMID41760894

DOI10.1038/s41598-026-41989-z

PMCPMC13049086

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.